Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome
Sponsor: Soleno Therapeutics, Inc.
A PHASE3 clinical study on Prader-Willi Syndrome, this trial is ongoing. The trial is conducted by Soleno Therapeutics, Inc. and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Feb 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Soleno Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .